CXC型趋化因子配体10与CXC型趋化因子配体12在乳腺癌组织的表达及其临床意义  

Expression and clinical significance of chemokines CXC tchemokine ligand 10 and CXC tchemokine ligand 12 in breast cancer tissues

作　　者：李静怡 王亭亭[2] 李冲[2] 李珊[2] 郑丽丽[2] Li Jingyi;Wang Tingting;Li Chong;Li Shan;Zheng Lili(Department of Plastic Surgery,Beijing Tiantan Hospital Affiliated to Capital Medical University,Beijing100050,China;Department of Endocrinology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou450052,China)

机构地区：[1]首都医科大学附属北京天坛医院医疗美容科,100050 [2]郑州大学第一附属医院内分泌科,450052

出　　处：《中华实验外科杂志》2019年第7期1283-1286,共4页Chinese Journal of Experimental Surgery

基　　金：国家自然科学基金(81601726).

摘　　要：目的探讨CXC型趋化因子配体10(CXCL10)与CXC型趋化因子配体12(CXCL12)蛋白在乳腺癌组织中表达及其与临床病理特征的关系.方法采用实时定量反转录聚合酶链反应(RT-qPCR)法及免疫组织化学技术检测趋化因子CXCL10与CXCL12在122例乳腺癌组织及相应的癌旁组织表达,并分析其表达差异与临床病理特征的相关性.应用SPSS 20.0统计软件分析,计量资料统计描述以均值±标准差(Mean±SD)表示.组间mRNA差异比较采用配对t检验,趋化因子蛋白与临床病理因素之间的评估采用χ^2检验及秩和检验,多个独立样本采用Kruskal-Wallis H检验.结果趋化因子CXCL10、CXCL12 mRNA在乳腺癌组织高表达(1.10±2.02比0.46±1.33、1.24±1.36比0.72±0.95),差异有统计学意义(t=2.959、3.045,P<0.01).免疫组织化学法检测显示CXCL10、CXCL12蛋白在乳腺癌组织中的表达率高于癌旁组织(44.3%比18.0%、60.7%比12.3%),差异有统计学意义(χ^2=19.569、61.570,P<0.01),与患者年龄、肿瘤大小、人表皮生长因子受体2 (Her-2)状态及激素受体状态均无明显相关性((χ^2=0.663、0.197、0.804、1.320、0.342、1.277、0.062、0.000,P>0.05).CXCL10在TNM分期为Ⅲ/Ⅳ期或伴有淋巴结转移的浸润性乳腺癌中的表达明显增高(χ^2=12.285、9.240,P<0.05),而CXCL12的表达与TNM分期及淋巴结转移无明显相关(χ^2=2.754、3.640,P>0.05).结论趋化因子CXCL10、CXCL12可能与乳腺癌的发生、发展有关,CXCL10可能与乳腺癌的淋巴结转移及恶性进展密切相关.Objective To research the expression of chemokines CXC tchemokine ligand 10 (CXCL10) and CXC tchemokine ligand 12 (CXCL12) in breast cancer tissues and the correlation with clinicopathological characteristics. MethodsThe expression of chemokines CXCL10/CXCL12 was detected in 122 breast cancer tissues and tissues adjacent to cancer by real-time quantitative reverse transcriptase-polymerase chain reaction (RT-qPCR) and immunohistochemistry. The correlation between the expression difference and the clinicopathological characteristics was analyzed. ResultsChemokines CXCL10 and CXCL12 mRNA expression was significantly higher in breast cancer tissues than in adjacent tissues (1.10±2.02 vs. 0.46±1.33, t=2.959, P<0.01;1.24±1.36 vs. 0.72±0.95, t=3.045, P<0.01). The expression rate of CXCL10 and CXCL12 proteins in breast cancer tissues was significantly higher than that in adjacent tissues (44.3% vs. 18.0%, and 60.7% vs. 12.3%,χ^2=19.569, 61.570, P<0.01), which had no relevance to the patient age, tumor size, states of human epidermal growth factor receptor-2 (Her-2) and hormone receptors (χ^2=0.663、0.197、0.804、1.320、0.342、1.277、0.062、0.000, P>0.05). The expression of CXCL10 in invasive breast cancer with TNM stage of Ⅲ/Ⅳ or with lymph node metastasis was significantly increased (χ^2=12.285, 9.240, P<0.05), while the expression of CXCL12 had no relevance to the TNM staging and the lymph node metastasis (χ^2=2.754, 3.640, P>0.05). ConclusionChemokines CXCL10 and CXCL12 may be related to the occurrence and development of breast cancer, and CXCL10 may be closely related to lymph node metastasis and malignant progression of breast cancer.

关 键 词：乳腺癌 趋化因子 CXC型趋化因子配体10 CXC型趋化因子配体12 

分 类 号：R737.9[医药卫生—肿瘤]